The mismatch repair process corrects errors in newly synthesized DNA. In this issue, Modrich and colleagues (Kadyrov et al., 2006) show that a component of the human mismatch repair machinery, MutLα, has endonuclease activity. MutLα introduces single-strand breaks near the mismatch and thus generates new entry points for the exonuclease EXOI to degrade the strand containing the mismatch.
Everyone has experienced the frustration of purchasing defective merchandise. Most often, the fault lies not in design but in production. Manufacturing good products depends on the level of quality control in the factory that makes them. When properly deployed, quality-control inspectors monitor each manufacturing step and take defective products out of the assembly line to be repaired or recycled. Ineffective controls are detrimental to the company's long-term viability. In biology, living cells are literally little factories that churn out thousands of new molecules of varying shapes, sizes, and complexity every minute. Similarly, their survival depends on efficient quality-control mechanisms that ensure molecules are correctly synthesized.
In protein quality control, the first step is recognition. The system must be able to distinguish between molecules that are actively folding, fully folded, and misfolded. Accurate discrimination of the three forms is essential in the endoplasmic reticulum (ER) because each form is handled differently. Actively folding proteins are retained in the ER and shielded from degradation pathways, folded proteins destined for export are packaged into transport vesicles, and misfolded proteins are retained and sorted for degradation. Once the determination is made, misfolded proteins are targeted to processing sites on the ER membrane for their extraction through a conduit whose identity is still unknown. When at least part of the substrate is exposed to the cytosol, E2 ubiquitin-conjugating enzymes and E3 ligases attach polyubiquitin tags to the protein, thus condemning it for destruction. The substrates are fully extracted from the membranes by the Cdc48p AAA-ATPase complex and degraded by the 26S proteasome in the cytosol (for review, see Romisch, 2005) . These terminal steps of ER quality control have been termed ER-associated degradation or ERAD. In this issue of Cell, Carvalho et al. (2006) and Denic et al. (2006) shed light on the specificity of this degradation pathway by demonstrating that distinct protein complexes form sites of recognition, ubiquitination, and extraction for specific substrate classes.
Proteins transiting the ER can be soluble or membrane bound with significant portions in the lumen, membrane, and cytosol. To accommodate the topological diversity, distinct pathways work side by side to monitor misfolding. Substrates are targeted to an appropriate ERAD pathway depending on the site of the misfolded lesion. Membrane and soluble proteins with luminal lesions are targeted to the ERAD-L pathway whereas membrane proteins with misfolded cytoplasmic domains use the ERAD-C pathway (Vashist and Ng, 2004) . Although ERAD-L and ERAD-C can be defined by distinct factors, how these factors are physically arranged as part of a system to carry out ERAD was unknown. Both studies were performed in budding yeast due to the availability of mutant strains and well-characterized ERAD substrates. As most components of ERAD are evolutionarily conserved, the basic conclusions derived from these studies are likely to be applicable to all eukaryotes. Carvalho et al. (2006) engineered tandem affinity purification (TAP) tags into Hrd1p and Doa10p. The resulting proteins and their partners were purified and identified by mass spectrometry. Reassuringly, nearly all the partner proteins found were already known to be involved in ERAD. What was interesting was the composition of each complex ( Figure  1 ). The Doa10p complex is relatively simple. Aside from Doa10p (the E3 ligase), it contains an E2 complex (Ubc7p and its membrane-anchoring factor Cue1p) and the Cdc48p complex (the AAA-ATPase Cdc48p, its cofactors Ufd1 and Npl4, and its membrane anchorage protein Ubx2p (Gardner et al., 2000) . Hrd3p copurified with TAPtagged Hrd1p as anticipated. The Ubc7p/Cue1p dimer and the Cdc48p complex, partners of Doa10p, were also found in complex with Hrd1p. However, this is where the similarities end. Additional factors that are unique to the complex, including Der1p, Yos9p, and Usa1p, were purified (Figure 1 ). Der1p is a small protein that spans the ER membrane four times. It was one of the first ERAD factors identified and it comes in direct contact with substrates, yet its function remains unclear (Knop et al., 1996) . Yos9p is a luminal lectin-like protein that specifically binds misfolded glycoproteins in ERAD (reviewed in Cormier et al., 2005) , and Usa1p is a new factor with a large cytosolic domain and two transmembrane segments. Analysis of pathway-specific substrates showed that, like Der1p and Yos9p, Usa1p is a component of the ERAD-L pathway. Its role is integral as it is needed to link Der1p to the Hrd1p ligase. Interestingly, proteins with disrupted transmembrane domains degrade independently of these factors, but require only Hrd1p and Hrd3p. For this, the authors proposed a new pathway termed ERAD-M. Whether ERAD-M substrates require additional factors for their recognition, as ERAD-L substrates do, is uncertain. Native purification of Yos9p by Denic et al. (2006) yielded the same complex of proteins as TAP-tagged Hrd1p and two additional factors, Emp47p and Kar2p. Emp47p is an interesting protein because it plays roles in vesicular transport. This may be relevant to some ERAD-L substrates that can traffic between the ER and Golgi. The chaperone Kar2p (also known as BiP) binds substrates and keeps them soluble for ERAD (Nishikawa et al., 2001 ). The new data indicate that Kar2p associates directly with Yos9p, independently of its peptide binding activity. Although the significance of this interaction is unclear, the arrangement of Yos9p within the ERAD-L complex has provided important clues (Figure 1 ). Previous studies have suggested that Yos9p may function as a substrate receptor, based on its ability to discriminate between folded and misfolded proteins (reviewed in Cormier et al., 2005) . Hrd3p can also interact with misfolded substrates (Denic et al., 2006; Gauss et al., 2006) . Denic et al. (2006) (Denic et al., 2006; Gauss et al., 2006) . However, acceptance of the substrate for ERAD requires the additional presence of a site-specific glycan group processed by α-mannosidase I. The slow enzymatic activity of the enzyme has been proposed to serve as a timer for folding (Jakob et al., 1998) , indicating that "misfolded" proteins might look similar to actively folding proteins, except that they have exceeded their allotted time to fold. Unfolded proteins bearing the resulting GlcNac 2 -Man 8 glycan structure are deemed misfolded after inspection by Yos9p/Hrd3p and degraded.
Together, these studies bring us closer to a unified view of ER quality control that can account for the diversity of proteins that traffic through the organelle. We now know that distinct protein complexes in the ER membrane function to receive and inspect unfolded proteins. The E3 ubiquitin ligases Hrd1p and Doa10p organize factors used for the recognition, ubiquitination, and extraction of substrates. Indeed, Hrd1p provides the direct physical link between recognition events in the ER lumen and ubiquitination and extraction activities in the cytosol (Carvalho et al., 2006; Denic et al., 2006; Gauss et al., 2006) . However, many pressing questions remain. Left out of the discussion is a second nonredundant lectin, Htm1p (EDEM in mammals), which is crucial in ERAD-L. Also, how substrates are moved to the cytosol remains elusive. The identity of the dislocation pore in ERAD-L remains controversial and whether such a conduit is even needed in ERAD-C and ERAD-M is unknown. Unlike the Hrd1p complex, there are no clear ideas on how the Doa10p complex participates in selecting substrates. There is no doubt, however, that the crucial framework these new studies provides will accelerate the resolution of these and other mysteries of how molecular inspectors carry out their work in ER quality control.
Removal of errors from newly synthesized DNA by the mismatch repair (MMR) machinery increases the fidelity of the replication process by up to three orders of magnitude. Moreover, the inactivation of genes involved in MMR by mutation or epigenetic silencing leads to a substantial increase in mutation frequency, and in mammals, loss of MMR promotes cancer of the colon and other organs (Jiricny, 2006) . Given the importance of the MMR system in the maintenance of genomic stability, the study of the molecular mechanisms underpinning this process is of substantial interest.
The human MMR process has been recently reconstituted in vitro using purified recombinant constituents. This work has shown that the degradation of the mismatch-containing strand from a preexisting nick or gap is bidirectional-that is, it can take place irrespective of whether this break is situated 5′ or 3′ to the mismatch. This observation has been puzzling because the reconstituted system uses only a single exonuclease, EXOI, which degrades DNA in a 5′-to-3′ direction. Thus, it has been difficult to explain how EXOI degrades the mismatch-containing strand when the mismatch is 5′ to the preexisting nick or gap. Kadyrov et al. (2006) now show how this can occur: A component of the MMR machinery, MutLα, possesses an endonuclease activity that introduces single-strand breaks selectively into the discontinuous strand. These new breaks then serve as targets for EXOI degradation. This allows the MMR machinery
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